A practical reference on Angiotensin IV analog: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-12-25. Anything still debated is marked as such rather than presented as settled.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Modeled on angiotensin IV |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Research codes vary by supplier |
| Appearance | White to off-white powder | Typical for lyophilized peptides |
| Solubility | Soluble in organic solvents; limited in water | Formulation dependent |
| Typical storage | −20 °C, desiccated, protected from light | Stability depends on purity and container |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
"All [prisoners in Iraq] except those held by the Ministry of Justice are, technically speaking, held against the law because the Ministry of Justice is the only authority that is empowered by law to detain, to hold anybody in prison. "Essentially none of these people have any real recourse to protection and therefore we speak ... of a total breakdown in the protection of the individual in this country. "It's very rare to get judges ordering you to be released and effectively the police respecting that order. "We have cases also where the judge who has ordered a group of people to be released, about 50-60 people, and the police, the Interior Ministry simply refuses. "We have another case in another part of the country where the judge was actually the subject of reprisal for having found people not getting, as ordered, their release. "The judge is now in jail. "The judiciary has a lot to answer for in this country. It is really not carrying out its duties," he said, adding that bribes were sometimes paid for jobs in the judiciary and police. "This is not denied," Pace said. "This is symptomatic of the corruption problems in this country and stands in the way of any kind of rule of law."
== History == Groups of grape pits dated to 8000 BCE show early evidence of juice production, although it is thought that the grapes may have been alternatively used to produce wine. One of the first regularly produced juices was lemonade, which appeared in 16th-century Italy as an import after its conception in the Middle East. Orange juice originated in the 17th century. In the 18th century, James Lind linked citrus fruits to the prevention of scurvy, which, a century later, led to the implementation of the Merchant Shipping Act 1867, requiring all ocean-bound British ships to carry citrus-based juice on board. In 1869, a dentist by the name of Thomas B. Welch developed a pasteurization method that allowed for the storage of juice without the juice fermenting into alcohol. His method involved filtering squeezed grape juice into bottles, sealing them with cork and wax, and then placing them in boiling water. This method kills the yeast responsible for fermentation. He then sold his new product as "Dr. Welch's Unfermented Wine". In the late 18th-century United States, the circulation of foreign fruit juices was heavily regulated by tariffs. The McKinley Tariff Act of 1890 increased import taxes from 38 to 49.5 percent and set taxes on fruit juices based on the alcohol content of the drink. Juices with 18% or less alcohol were taxed at 60 cents per gallon, while anything above 18% was taxed at US$2.50 per proof gallon.
The game won several publication awards, as well as "Computer Action Game of the Year" from the Academy of Interactive Arts & Sciences during the 3rd Annual Interactive Achievement Awards. The editors of PC Gamer US presented Opposing Force with their 1999 "Best Expansion Pack" award, and nominated it as 1999's overall best game of the year, although it lost the latter prize to Homeworld. They wrote that Opposing Force "makes history by becoming the first expansion pack to be considered for Game of the Year. Yes, it really is that good."
δDs of fatty acids in living organisms, are typically −73‰ to −237‰. The δDs of individual fatty acids vary widely between cultures (−362‰ to +331‰), but typically by less than around 30‰ between different fatty acids from the same species. The differences in δD for the compounds within the same lipid class is generally less than 50‰, whereas the difference falls in the range of 50‰–150‰ for the compounds in different lipid classes. δDs for typical lipid groups are determined using the following equation:
Sources: en.wikipedia.org
Pressure ulcers, also known as pressure sores, bed sores or pressure injuries, are localised damage to the skin and/or underlying tissue that usually occurs over a bony prominence as a result of usually long-term pressure, or pressure in combination with shear or friction. The most common sites are the skin overlying the sacrum, coccyx, heels, and hips, though other sites can be affected, such as the elbows, knees, ankles, back of shoulders, or the back of the cranium. Pressure ulcers occur due to pressure applied to soft tissue which results in completely or partially obstructed blood flow to the soft tissue. Shear is also a cause, as it can pull on blood vessels that feed the skin. Pressure ulcers most commonly develop in individuals who are not moving about, such as those who are on chronic bedrest or consistently use a wheelchair. It is widely believed that other factors can influence the tolerance of skin for pressure and shear, thereby increasing the risk of pressure ulcer development. These factors are protein-calorie malnutrition, microclimate (skin wetness caused by sweating or incontinence), diseases that reduce blood flow to the skin, such as arteriosclerosis, or diseases that reduce the sensation in the skin, such as paralysis or neuropathy. The healing of pressure ulcers may be slowed by a person's age, medical conditions (such as arteriosclerosis, diabetes or infection), smoking or medications such as anti-inflammatory drugs.
=== Infections and infestations === Apple scab, an apple tree (genus Malus) fungal disease caused by Venturia inaequalis Black scab, a potato fungal disease caused by Synchytrium endobioticum Common scab, a plant bacterial disease caused by Streptomyces species Fusarium head blight, a fungal disease of plants, e.g., grain crops (especially wheat and oats), golf course grass, caused by the several species of Fusarium Pear scab, a pear fungal disease caused by Venturia pirina or Fusicladium pyrorum Poinsettia scab, a spot anthracnose disease caused by Sphaceloma poinsettiae Powdery scab, a disease of the skin of potatoes caused by the protozoa Spongospora subterranea Sheep scab, a skin disease of sheep caused by the mite Psoroptes ovis
=== January === 1 January – A visit by Thor the Walrus to Scarborough harbour, North Yorkshire overnight on New Year's Eve results in the town's New Year fireworks celebrations being cancelled to let the walrus rest for his journey to the Arctic. He was previously spotted at Pagham Harbour, Calshot, Hampshire in December 2022. 2 January Three people are killed by a fire at the New County Hotel in Perth, Scotland. Thor the Walrus makes an appearance in Blyth, Northumberland. 3 January – 40,000 railway workers who are members of the RMT union hold the first of two 48-hour strikes this week, severely disrupting train services in England, Scotland, and Wales. 5 January The government confirms it will not go ahead with a plan to privatise Channel 4. The Met Office confirms that 2022 was the UK's warmest year since records began in 1884, with an average annual temperature above 10 °C (50 °F) for the first time. BioNTech announces a strategic partnership with the UK government to provide up to 10,000 patients with personalised mRNA cancer immunotherapies by 2030. 6 January – COVID-19 in the UK: Almost three million people were infected with COVID-19 over the Christmas period (the highest since July 2022), the latest Office for National Statistics data suggests, with one in 20 having the virus in England, one in 18 in Wales, one in 25 in Scotland and one in 16 in Northern Ireland. XBB.1.5, the new Omicron variant of the virus, is believed to be responsible for one in 200 infections in the UK.
=== Reaction === The peptide to be sequenced is adsorbed onto a solid surface. One common substrate is glass fibre coated with polybrene, a cationic polymer. The Edman reagent, phenylisothiocyanate (PITC), is added to the adsorbed peptide, together with a mildly basic buffer solution of 12% trimethylamine. This reacts with the amine group of the N-terminal amino acid. The terminal amino acid can then be selectively detached by the addition of anhydrous acid. The derivative then isomerises to give a substituted phenylthiohydantoin, which can be washed off and identified by chromatography, and the cycle can be repeated. The efficiency of each step is about 98%, which allows about 50 amino acids to be reliably determined.
The ruby laser was developed in 1960 by Theodore Maiman (1927-2007) as the first laser based on the ruby maser. Soon after, the dangers of lasers were discovered, especially for the eyes and skin, due to the laser's low penetration depth. Lasers have numerous applications in technology and research as well as in everyday life, from simple laser pointers to distance measuring devices, cutting and welding tools, reproduction of optical storage media such as CDs, DVDs and Blu-ray discs, communication, laser scalpels and other devices using laser light in everyday medical practice. The Radiation Protection Commission requires that laser applications on human skin be performed only by a specially trained physician. Lasers are also used for show effects in discotheques and at events.
Sources: en.wikipedia.org
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.
It is generally not regulated as a dietary supplement. Products are often sold as research chemicals. That status affects purity, labeling, and legal availability.
Dihexa itself is not a standard endogenous peptide. It is synthesized and modeled on angiotensin IV. Angiotensin IV occurs naturally as a fragment of angiotensin II.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.